BRCA gene mutations are present in about 10% of pancreatic adenocarcinoma cases, with four cases studied where three had BRCA2 and one had BRCA1 mutations.
Two patients received neoadjuvant treatment with Folfirinox and radiotherapy, leading to successful surgeries with complete pathological responses.
Detection of BRCA mutations offers potential for personalized treatment, improving survival rates and reducing local recurrence in pancreatic cancer patients.